We observed that PAK4 KO tumors, regardless of anti-PD-1 treatment, significantly increased the percentage of CD103+ DC (Fig. 1A), a subset of dendritic cells that have been described to excel at cross-presenting tumor antigens (31). The gene discussed is PAK4; the disease is neoplasm.